Get Social With Us

BPTC Senior Consultant Dr. Tiffany Rau to Judge First Annual Biotechnical Design Competition Finals in Barcelona, Spain

Joint European and US teams present designs at the 4th European Congress of Applied Biotechnology, October 1-5, 2017

Woburn, Mass., September 27 (Business Wire) – Tiffany D. Rau, Ph.D., who recently joined BioProcess Technology Consultants, Inc. (BPTC) as a Senior Consultant, is an organizer of the First Annual Biotechnical Design Competition and a member of the four-judge panel at the Competition finals in October. The international competition challenges master and postgraduate students from the US and Europe to work together to design a complete biosimilar manufacturing process. The top three of the starting six teams will present their designs to delegates attending the 4th European Congress of Applied Biotechnology, October 1-5, 2017, in Barcelona, Spain.

Speaking on behalf of her fellow organizers, Dr. Rau said, “We see this international competition as a remarkable learning opportunity for these graduate students, especially when one considers that each team is composed of U.S. and European students. Today, biotechnology is a global industry and multinational teams are becoming the norm. I hope we can double the number of participating teams in the near future.”

The Competition is sponsored by the European Society for Biochemical Engineering Sciences (ESBES), in cooperation with the American Chemical Society’s, Biochemical Technology Division (ACS-BIOT). Professor Jarka Glassey, ESBES VP and Newcastle University, UK added “ESBES is delighted with the success of the first design completion, extending the long-term collaboration between ESBES and ACS-Biot, and look forward to having even greater numbers of European and US graduate student teams.” Professor William Kelly of Villanova University and BIOT executive board member, indicated that “this competition provides a unique opportunity for sponsoring companies to engage with some of the brightest future biochemical engineers”.

Dr. Rau, an expert in mammalian and microbial systems for production of biopharmaceuticals from development to post-commercial cGMP manufacturing is a Six Sigma Master Black Belt who earned her Ph.D. in chemical engineering from Vanderbilt University. She has designed and led bioprocessing projects for startups and multi-national pharmaceutical companies in the U.S. and overseas, including Eli Lilly and Company, Evonik-Degussa, Pall Corp., and GlaxoSmithKline. Dr. Rau has been instrumental in implementing initiatives that bring research, development, and manufacturing together, increasing speed to market and minimizing technology transfer challenges.

“As the biopharmaceutical industry continues its unprecedented growth, the addition of an internationally recognized expert like Dr. Rau to our team further expands our existing knowledge base in the critical upstream processing areas for biologics, allowing us to better serve our clients and support the development and commercialization of new biopharmaceutical products,” said Howard. L. Levine, Ph.D., President and CEO of BPTC. “We are pleased that Dr. Rau has joined BPTC and especially proud of her leadership role in organizing the Biotechnical Design Competition.”

“I’m thrilled to have the opportunity to work with BPTC’s internationally recognized consulting experts and look forward to helping our clients address the challenging CMC issues associated with biopharmaceutical product development.” said Dr. Rau.

About BioProcess Technology Consultants

Founded in 1994, BPTC is the recognized worldwide leader in biologics CMC consulting, providing a full range of technical, regulatory, and strategic assistance to pharmaceutical and biotechnology companies in the development and commercialization of biopharmaceutical products. The company works with clients globally to find and apply solutions to the challenges of biopharmaceutical product development from clone to commercial®. BPTC helps develop manufacturing processes and strategies that enhance the overall value of client companies and accelerate the advancement of new products from clone to clinic®. BPTC also helps investors make informed decisions by providing technical and business evaluations of new products and technologies and product discovery, development, and commercialization plans of potential investments and existing portfolio companies. For more information about BPTC, visit Follow us on Twitter at @bptcGlobal and LinkedIn at